Atrasentan (ABT-627/A-127722) is an ETA receptor antagonist that was originally discovered by Abbott (AbbVie) in the 1990s to treat prostate cancer. Unfortunately, clinical data with the compound in prostate cancer was insufficient for approval, and AbbVie pivoted the compound to chronic kidney diseases instead, ultimately conducting a large, 5,000+ patient trial (SONAR) that was published in 2019.
15 minute read
Oct. 10, 2023
A 1990’s Abbott Candidate Revived by a Biotech for Renal Health
atrasentan
oral ETA receptor antagonist Ph. III for IgAN, 0.75 mg QD, Ph. II in Alport Syndrome ligand-based design from prior ETAR antagonists Acquisition announcement, June 12, 2023 Abbott Labs (AbbVie) / Chinook Therapeutics
Author:
Editor:
Loading...
